Cargando…

Targeting VEGF in canine oxygen-induced retinopathy – a model for human retinopathy of prematurity

Development of the dog superficial retinal vasculature is similar to the mechanism of human retinal vasculature development; they both develop by vasculogenesis, differentiation, and assembly of vascular precursors called angioblasts. Canine oxygen-induced retinopathy (OIR) was first developed by Ar...

Descripción completa

Detalles Bibliográficos
Autores principales: McLeod, D Scott, Lutty, Gerard A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398743/
https://www.ncbi.nlm.nih.gov/pubmed/28539802
http://dx.doi.org/10.2147/EB.S94443
_version_ 1783230521407438848
author McLeod, D Scott
Lutty, Gerard A
author_facet McLeod, D Scott
Lutty, Gerard A
author_sort McLeod, D Scott
collection PubMed
description Development of the dog superficial retinal vasculature is similar to the mechanism of human retinal vasculature development; they both develop by vasculogenesis, differentiation, and assembly of vascular precursors called angioblasts. Canine oxygen-induced retinopathy (OIR) was first developed by Arnall Patz in an effort to experimentally determine the effects of hyperoxia on the development of the retinal vasculature. The canine OIR model has many characteristics in common with human retinopathy of prematurity. Exposure of 1-day-old dogs to hyperoxia for 4 days causes a vaso-obliteration throughout the retina. Vasoproliferation, after the animals have returned to room air, is robust. The initial small preretinal neovascular formations anastomose to form large preretinal membranes that eventually cause tractional retinal folds. The end-stage pathology of the canine model is similar to stage IV human retinopathy of prematurity. Therefore, canine OIR is an excellent forum to evaluate the response to drugs targeting VEGF and its receptors. Evaluation of an antibody to VEGF-R2 and the VEGF-Trap demonstrated that doses should be titered down so that preretinal neovascularization is inhibited but retinal revascularization is able to proceed, vascularizing peripheral retina and preventing it from being a source of VEGF.
format Online
Article
Text
id pubmed-5398743
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-53987432017-05-24 Targeting VEGF in canine oxygen-induced retinopathy – a model for human retinopathy of prematurity McLeod, D Scott Lutty, Gerard A Eye Brain Original Research Development of the dog superficial retinal vasculature is similar to the mechanism of human retinal vasculature development; they both develop by vasculogenesis, differentiation, and assembly of vascular precursors called angioblasts. Canine oxygen-induced retinopathy (OIR) was first developed by Arnall Patz in an effort to experimentally determine the effects of hyperoxia on the development of the retinal vasculature. The canine OIR model has many characteristics in common with human retinopathy of prematurity. Exposure of 1-day-old dogs to hyperoxia for 4 days causes a vaso-obliteration throughout the retina. Vasoproliferation, after the animals have returned to room air, is robust. The initial small preretinal neovascular formations anastomose to form large preretinal membranes that eventually cause tractional retinal folds. The end-stage pathology of the canine model is similar to stage IV human retinopathy of prematurity. Therefore, canine OIR is an excellent forum to evaluate the response to drugs targeting VEGF and its receptors. Evaluation of an antibody to VEGF-R2 and the VEGF-Trap demonstrated that doses should be titered down so that preretinal neovascularization is inhibited but retinal revascularization is able to proceed, vascularizing peripheral retina and preventing it from being a source of VEGF. Dove Medical Press 2016-05-20 /pmc/articles/PMC5398743/ /pubmed/28539802 http://dx.doi.org/10.2147/EB.S94443 Text en © 2016 McLeod and Lutty. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
McLeod, D Scott
Lutty, Gerard A
Targeting VEGF in canine oxygen-induced retinopathy – a model for human retinopathy of prematurity
title Targeting VEGF in canine oxygen-induced retinopathy – a model for human retinopathy of prematurity
title_full Targeting VEGF in canine oxygen-induced retinopathy – a model for human retinopathy of prematurity
title_fullStr Targeting VEGF in canine oxygen-induced retinopathy – a model for human retinopathy of prematurity
title_full_unstemmed Targeting VEGF in canine oxygen-induced retinopathy – a model for human retinopathy of prematurity
title_short Targeting VEGF in canine oxygen-induced retinopathy – a model for human retinopathy of prematurity
title_sort targeting vegf in canine oxygen-induced retinopathy – a model for human retinopathy of prematurity
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398743/
https://www.ncbi.nlm.nih.gov/pubmed/28539802
http://dx.doi.org/10.2147/EB.S94443
work_keys_str_mv AT mcleoddscott targetingvegfincanineoxygeninducedretinopathyamodelforhumanretinopathyofprematurity
AT luttygerarda targetingvegfincanineoxygeninducedretinopathyamodelforhumanretinopathyofprematurity